The studies were subsequently strongly supported by observation that patients with chronic granulomatous disease (CGD), with impaired NADPH oxidase activity, did not release NETs but that this could be restored by a targeted gene therapy (Bianchi et al. 2009). This evidence concerns the gene FMO5 and chronic granulomatous disease.